The chief human resources officer of Health Catalyst sells $37,348 worth of stock to Investing.com
Linda Llewelyn, Chief Human Resources Officer at catalyst of health Inch. (NASDAQ: ), recently sold shares of the company, according to a filing with the Securities and Exchange Commission. On January 15, Llewelyn sold 6,442 shares of common stock at an average price of $5.7976 per share, for a total of approximately $37,348. Following this transaction, Llewelyn retains ownership of 92,260 shares of the company. This sale was made pursuant to a pre-arranged trading plan established in March 2024, pursuant to Rule 10b5-1. The sale comes as Health Catalyst is trading near a 52-week low of $5.35, with shares down more than 20% in the past week. According to InvestingPro analysis, the stock appears to be undervalued at current levels, with analysts predicting profitability this year despite recent market pressure. InvestingPro subscribers have access to 8 additional key Health Catalyst insights, including detailed financial health scores and comprehensive valuation metrics.
In other recent news, Health Catalyst has been at the center of several notable developments. The company announced a definitive agreement to acquire Upfront Healthcare Services (NASDAQ: ), a patient engagement platform provider, which is expected to close in the first quarter of 2025. The acquisition aims to enhance Health Catalyst’s existing patient engagement portfolio and simplify care for patients.
Health Catalyst also reported its positive Q3 2024 financial results, with revenue shifting back towards software. Analyst firms such as KeyBanc Capital Markets, Piper Sandler and Stephens showed optimism for the company’s performance, upgrading the stock and raising its price target. KeyBanc upgraded Health Catalyst from Sector Weight to Overweight, while Piper Sandler and Stephens raised their price targets on the company’s stock.
In terms of analyst ratings, RBC Capital cut the stock price target for Health Catalyst to $7, maintaining a Sector Perform rating. This decision reflects the company’s cautious stance as they monitor Health Catalyst’s ability to convert new client bookings into sustainable revenue growth. However, the company expressed optimism about Health Catalyst’s bookings forecast for 2025, forecasting about 40 net new clients.
These are recent developments that provide investors with insight into Health Catalyst’s financial health and growth trajectory. Company actions and financial results, along with perspectives from various analyst firms, offer a snapshot of Health Catalyst’s current business environment.
This article was generated with the help of AI and reviewed by an editor. See our T&C for more information.
